UBS Group
TDOC icon

UBS Group’s Teladoc Health TDOC Stock Holding History

UBS Group’s Portfolio TDOC Stock Details TDOC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-203,900
Closed -$1.43M – 11153
2025
Q4 		$1.43M Sell
203,900
-1,300
-0.6% -$10.2K ﹤0.01% 5265
2025
Q3 		$1.59M Buy
205,200
+1,300
+0.6% +$10.1K ﹤0.01% 5179
2025
Q2 		$1.78M Sell
203,900
-11,400
-5% -$82.6K ﹤0.01% 4940
2025
Q1 		$1.71M Buy
215,300
+10,300
+5% +$104K ﹤0.01% 4836
2024
Q4 		$1.86M Hold
205,000
– – ﹤0.01% 4783
2024
Q3 		$1.88M Sell
205,000
-833,400
-80% -$6.9M ﹤0.01% 4051
2024
Q2 		$10.2M Buy
1,038,400
+987,300
+1,932% +$12M ﹤0.01% 2202
2024
Q1 		$772K Sell
51,100
-125,000
-71% -$2.27M ﹤0.01% 4824
2023
Q4 		$3.79M Sell
176,100
-90,000
-34% -$1.66M ﹤0.01% 3071
2023
Q3 		$4.95M Buy
266,100
+5,600
+2% +$131K ﹤0.01% 2571
2023
Q2 		$6.6M Sell
260,500
-55,100
-17% -$1.39M ﹤0.01% 2318
2023
Q1 		$8.17M Sell
315,600
-301,800
-49% -$8.08M ﹤0.01% 2056
2022
Q4 		$14.6M Sell
617,400
-117,200
-16% -$3.16M 0.01% 1645
2022
Q3 		$18.6M Buy
734,600
+369,800
+101% +$13M 0.01% 1327
2022
Q2 		$12.1M Buy
364,800
+196,000
+116% +$8.33M 0.01% 1672
2022
Q1 		$12.2M Sell
168,800
-170,000
-50% -$12.2M ﹤0.01% 1793
2021
Q4 		$31.1M Buy
338,800
+172,589
+104% +$20.6M 0.01% 1264
2021
Q3 		$21.1M Buy
166,211
+105,612
+174% +$15.4M 0.01% 1470
2021
Q2 		$10.1M Sell
60,599
-5,272
-8% -$854K ﹤0.01% 2028
2021
Q1 		$12M Sell
65,871
-373,953
-85% -$86.7M ﹤0.01% 1801
2020
Q4 		$87.9M Buy
+439,824
New +$89.4M 0.03% 528
2020
Q3 		– Sell
-63,800
Closed -$12.2M – 8396
2020
Q2 		$12.2M Buy
+63,800
New +$11.2M 0.01% 1366
2017
Q1 		– Sell
-6,500
Closed -$107K – 7961
2016
Q4 		$107K Buy
+6,500
New +$110K ﹤0.01% 5246

Other funds holding TDOC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group's TDOC Position: Q1 2026 in Review

UBS Group increased its Teladoc Health (TDOC) stake by 15% in Q1 2026, buying an estimated $1.28M and bringing the position to 1,726,823 shares worth $9.41M. The position accounts for ﹤0.01% of the portfolio, ranked #3427.

UBS Group first reported a position in TDOC in Q3 2015 and has held it in 43 quarters since. The position peaked at $112M in Q2 2021. 322 funds tracked by Wall St. Rank hold TDOC as of Q1 2026.

  • UBS Group held 1,726,823 shares of Teladoc Health worth $9.41M as of Q1 2026.
  • UBS Group bought 228,272 Teladoc Health shares in Q1 2026, an estimated $1.28M.
  • Teladoc Health made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #3427 holding.
  • UBS Group first reported a position in Teladoc Health in Q3 2015 and has held it in 43 quarters since.
  • UBS Group's Teladoc Health position peaked at $112M in Q2 2021.
  • 322 funds tracked by Wall St. Rank held Teladoc Health as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.